You are using an older browser version. Please use a supported version for the best MSN experience.

Here's Why Alzamend Neuro Stock Is Shooting Higher Today

The Motley Fool logo The Motley Fool 7/23/2021 Cory Renauer
a person standing in a kitchen: Here's Why Alzamend Neuro Stock Is Shooting Higher Today © Provided by The Motley Fool Here's Why Alzamend Neuro Stock Is Shooting Higher Today

What happened

Shares of Alzamend Neuro (NASDAQ: ALZN), a biotechnology company in the pre-clinical stage, started Friday's trading 44% higher. Investors were thrilled with the positive results of a mouse toxicology study with an experimental new Alzheimer's disease treatment called AL002.

But the early gains have steadily faded away as investors realize today's announcement isn't terribly important. The stock was up just 6.5% as of 11:46 a.m. on Friday.

So what 

Alzheimer's disease (AD) affects more than 6 million Americans, and this number is on the rise. The only treatment approved to slow the progression of this fatal disease hasn't actually proved itself effective at improving patient outcomes, so demand for new drugs like AL002 is still sky-high.

a person standing in a kitchen: Scientists at work in a laboratory. © Getty Images Scientists at work in a laboratory.

Alzamend Neuro shares are rising today in response to a positive toxicology report from a mouse study with AL002. The report basically says they couldn't find any signs of brain damage caused by AL002 90 days after the mice received their last dose.

Bad mouse toxicology reports can derail programs before they begin, but they aren't worthy of a press release. Demand for AD drugs is so high that any positive news regarding experimental treatments can send related stocks through the roof.

Now what

AL002 isn't a drug itself. It's a patented method of withdrawing white blood cells that will mature to become dendritic cells and exposing them to amyloid-beta before reintroducing them into patients. It's supposed to make the immune system extra vigilant about cleaning up amyloid fragments before they can aggregate into plaques associated with AD.

Not finding evidence of neurological damage among mice after treating them with AL002 is a necessary step on the development path. But it tells us nothing about what effect, if any, it will have on AD patient outcomes.

If Alzamend eventually proves that AL002 can stop AD patients from worsening, the stock would provide enormous returns. Until we see some evidence that says this company's unusual approach actually works for people, it's probably best to watch this ultra-risky biotech stock from a safe distance.

SPONSORED:

10 stocks we like better than Alzamend Neuro, Inc.

When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Alzamend Neuro, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of June 7, 2021

 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

AdChoices
AdChoices
AdChoices

More from The Motley Fool

The Motley Fool
The Motley Fool
image beaconimage beaconimage beacon